<span item_type="fundamental" item_id="30e9a3410f591fc971d97cceb98c20be" counter_id="ST/US/PAVM" env="prod"></span><span item_type="announcement" item_id="648615685289084289" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 22 K, missing the estimate of USD 74 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -4.42.</p><p></p><h4>Operating Expenses</h4><ul><li>Operating expenses for PAVmed Inc. were approximately $8.1 million for the three months ended March 31, 2026, which included $0.2 million in stock-based compensation expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li><li>Total operating expenses for PAVmed Inc. were $8,057 thousand for the three months ended March 31, 2026, compared to $5,454 thousand for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>GAAP Net Loss Attributable to Common Stockholders</h4><ul><li>GAAP net loss attributable to common stockholders for PAVmed Inc. was approximately -$7.0 million for the three months ended March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li><li>Net income (loss) attributable to common stockholders for PAVmed Inc. was -$6,988 thousand for the three months ended March 31, 2026, compared to $17,695 thousand for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>Non-GAAP Adjusted Loss</h4><ul><li>The non-GAAP adjusted loss for PAVmed Inc. was approximately -$1.9 million for the three months ended March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li><li>Non-GAAP adjusted (loss) for PAVmed Inc. was -$1,851 thousand for the three months ended March 31, 2026, compared to -$910 thousand for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>Cash and Cash Equivalents</h4><ul><li>PAVmed Inc. had cash and cash equivalents of $6.5 million as of March 31, 2026, compared to $1.5 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>EsoGuard® Esophageal DNA Test Revenue</h4><ul><li>Lucid Diagnostics Inc. recognized $1.3 million in EsoGuard® Esophageal DNA Test revenue for the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>EsoGuard Tests Processed</h4><ul><li>Lucid Diagnostics Inc. processed 3,177 EsoGuard tests in the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>Cash Position (Lucid Diagnostics Inc.)</h4><ul><li>Lucid Diagnostics Inc. strengthened its balance sheet with an underwritten public offering of common stock, netting approximately $17 million in proceeds.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li><li>The company ended the first quarter of 2026 with $45 million in proforma cash, extending its runway into 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>PAVmed Inc. is positioned to focus on execution across its core businesses and evaluate additional asset acquisition opportunities aligned with its long-term growth strategy, following a simplified capital structure and strengthened balance sheet.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li><li>Veris Health Inc. expects to begin presubmission and testing activities soon for its implantable physiological monitor, in support of a planned FDA 510(k) submission, and continues to expand its commercial engagement with The Ohio State University’s James Cancer Hospital.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li><li>Lucid Diagnostics Inc. continues to build commercial momentum for EsoGuard with a strengthened balance sheet pending Medicare coverage.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/ex99-1.htm"></span></li></ul>

PAVmed | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22 K